<DOC>
	<DOCNO>NCT02725632</DOCNO>
	<brief_summary>This study design test whether SCN5A mRNA processing alter OSA patient , may contribute increase arrhythmic risk , whether process SCN5A mRNA modulate CPAP treatment . Specific aim : 1 . Compare sodium channel splice variant mild , moderate , severe OSA patient baseline 1 month CPAP treatment . In addition , baseline splice variant SCN5A OSA patient compare age-matched control group . 2 . Hypoxia-associated upstream regulator SCN5a mRNA splicing , Hypoxia-inducible factor 1-alpha ( HIF-1α ) , RNA Binding Motif Protein 25 ( RBM25 ) LUC7-Like 3 Pre-MRNA Splicing Factor ( LUC7L3 ) , examine OSA patient 1 month CPAP treatment .</brief_summary>
	<brief_title>Sodium Channel Splicing Obstructive Sleep Apnea ( SOCS-OSA )</brief_title>
	<detailed_description>BACKGROUND &amp; SIGNIFICANCE Obstructive sleep apnea ( OSA ) common disease estimate prevalence 3 % 7 % . It characterize recurrent episode partial complete collapse upper airway sleep , result hypopneas apnea , respectively . The collapse upper airway obstructed event result intermittent hypoxia , recurrent arousal sleep , metabolic disturbance poor quality life . Cardiac arrhythmias reportedly frequent patient OSA increase number apneic episode severity associate hypoxemia . Recent data Sleep Heart Health Study suggest severe sleep disorder 2- 4-fold-higher risk nocturnal complex arrhythmia . Even adjustment age , sex , BMI , prevalent coronary artery disease , patient sleep disorder increase likelihood atrial fibrillation , nonsustained ventricular tachycardia , complex ventricular ectopy . Continuous positive airway pressure ( CPAP ) first-line treatment patient OSA act pneumatic splint upper airway sleep corrects obstruction , improve daytime sleepiness quality life . Observational study suggest CPAP treatment reduces incidence cardiovascular event patient moderate sever OSA . Sodium channel integral membrane protein play central role conduction cardiac impulse myocytes cell His-Purkinje system . It multimeric complex consist α auxiliary β-subunit . The α subunit , SCN5A sufficient express functional channel . However , β subunit co-expression increase level channel expression alters voltage dependence inactivation . Mutations sodium channel result type 3 long QT syndrome ( LQT3 ) , Brugada syndrome , atrial fibrillation , congenital sick sinus syndrome , multifocal premature ventricular contraction ( PVCs ) , dilate cardiomyopathy . Recently , investigator discover abnormal sodium channel messenger RNA ( mRNA ) processing congestive heart failure ( CHF ) result reduce sodium channel range know associate sudden cardiac death . Three truncate SCN5A mRNA splice variant identify ( denote variant B ( E28B ) , variant C ( E28C ) , variant D ( E28D ) ) . Among , E28C E28D abundance increase 14.2 fold 3.8 fold respectively CHF patient compare control . The full length SCN5A mRNA ( E28A ) decrease 24.7 % patient CHF compare control . Moreover , key transcriptional regulatory molecule hypoxia , hypoxia-induced factor 1α ( HIF-1α ) , hypoxia-induced mRNA splice factor , RBM25 LUC7L3 , elevate human CHF tissue mediate vitro truncation SCN5A mRNA . Thus , study design test whether SCN5A mRNA processing alter OSA patient , may contribute increase arrhythmic risk , whether process SCN5A mRNA modulate CPAP treatment . SPECIFIC AIMS 1 . Compare sodium channel splice variant mild , moderate , severe OSA patient baseline 1 month CPAP treatment . In addition , baseline splice variant SCN5A OSA patient compare age-matched control group . 2 . Hypoxia-associated upstream regulator SCN5a mRNA splicing , HIF-1α , RBM25 LUC7L3 , examine OSA patient 1 month CPAP treatment .</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>OSA Eligibility Criteria : 1 . Age great 18 year 2 . Able provide inform consent 3 . New diagnosis OSA polysomnogram 4 . Agree CPAP treatment Control Eligibility Criteria : 1 . Age great 18 year 2 . Without OSA 3 . Able provide inform consent 1 . Not able give inform consent due psychological incapacity 2 . Chronic use hypnotic 6 week 3 . Current drug alcohol addiction 4 . Rhythm sinus enrollment 5 . Mandatory biventricular pace 6 . History heart transplant leave ventricular assist device ( LVAD ) 7 . Active use intravenous vasodilator , vasopressor inotropes 8 . Hemodialysis peritoneal dialysis 9 . Active infection include bacteremia 10 . Acute coronary syndrome ( ACS ) within 6 week 11 . Major trauma surgery within 6 week 12 . Malignant neoplastic disease active treatment include chemotherapy radiation therapy , life expectancy le 1 year 13 . Collagen vascular disease active treatment include steroid immunomodulating drug 14 . Systemic steroid use within 6 week 15 . Concomitant use investigational drug within 6 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Sodium channel</keyword>
	<keyword>splice variant</keyword>
	<keyword>sleep apnea syndrome</keyword>
</DOC>